#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14634	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2264	644.2	0	.	n	.	0	A69G	SNP	69	69	A	425	425	G	837	G	782	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14634	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2264	644.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1806	1806	T	820	T,C	755,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14634	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2264	644.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1540	1540	C	830	C	777	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27288	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3700	736.0	0	.	n	.	0	T695C	SNP	695	695	T	1103	1103	C	829	C	782	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27288	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3700	736.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2379	2379	C	886	C	827	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27288	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3700	736.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2453	2453	A	874	A	831	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27288	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3700	736.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	3005	3005	C	848	C,A	805,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2108	folP	855	855	100.0	folP.l15.c30.ctg.1	1799	117.0	1	SNP	p	R229S	1	.	.	685	687	AGC	1099	1101	AGC	220;220;219	A;G;C	204;206;203	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5280	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3301	159.0	1	SNP	p	S91F	1	.	.	271	273	TTC	566	568	TTC	174;175;177	T;T;C	167;167;165	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5280	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3301	159.0	1	SNP	p	G95N	0	.	.	283	285	GGC	578	580	GGC	166;168;166	G;G;C	159;162;161	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5280	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3301	159.0	1	SNP	p	D95G	1	.	.	283	285	GGC	578	580	GGC	166;168;166	G;G;C	159;162;161	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	1694	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1418	119.0	0	.	p	.	0	D79N	NONSYN	235	237	GAT	597	599	AAT	207;210;211	A;A;T	192;196;195	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	1694	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1418	119.0	1	SNP	p	G45D	0	.	.	133	135	GGC	495	497	GGC	214;215;214	G,T;G;C	198,1;198;198	mtrR.WHO_F_01564:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	750	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c30.ctg.1	1075	69.5	0	.	n	.	0	A197.	DEL	197	197	A	633	633	A	174	A	164	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4748	parC	2304	2304	99.87	parC.l6.c30.ctg.1	2902	163.1	0	.	p	.	0	E91G	NONSYN	271	273	GAG	553	555	GGG	189;188;188	G;G,A,T;G	179;175,2,1;180	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4748	parC	2304	2304	99.87	parC.l6.c30.ctg.1	2902	163.1	1	SNP	p	D86N	0	.	.	256	258	GAC	538	540	GAC	193;194;194	G;A,T;C	177;172,1;178	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4748	parC	2304	2304	99.87	parC.l6.c30.ctg.1	2902	163.1	1	SNP	p	S87W	0	.	.	259	261	AGT	541	543	AGT	194;193;189	A,C;G;T	180,1;180;174	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4748	parC	2304	2304	99.87	parC.l6.c30.ctg.1	2902	163.1	1	SNP	p	S87I	0	.	.	259	261	AGT	541	543	AGT	194;193;189	A,C;G;T	180,1;180;174	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4748	parC	2304	2304	99.87	parC.l6.c30.ctg.1	2902	163.1	1	SNP	p	S87R	0	.	.	259	261	AGT	541	543	AGT	194;193;189	A,C;G;T	180,1;180;174	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4748	parC	2304	2304	99.87	parC.l6.c30.ctg.1	2902	163.1	1	SNP	p	S88P	0	.	.	262	264	TCC	544	546	TCC	189;191;193	T;C;C	175;179;181	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4300	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2553	167.7	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1561	1563	CAC	221;222;221	C;A;C	199;204;202	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4300	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2553	167.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1510	1512	GGC	234;229;228	G;G;C	219;213;211	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.44.001	penA.44.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2443	173.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1287	1289	GCA	226;231;232	G;C,T;A	213;214,1;220	penA.44.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2443	173.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1290	1292	ATC	235;236;237	A;T;C	220;219;222	penA.44.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2443	173.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1302	1304	GTG	237;235;232	G;T;G	223;218;216	penA.44.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2443	173.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1302	1304	GTG	237;235;232	G;T;G	223;218;216	penA.44.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2443	173.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1806	1808	ACC	244;241;240	A;C,T;C,T	222;221,1;222,1	penA.44.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2443	173.2	1	SNP	p	T502V	0	.	.	1504	1506	ACG	1860	1862	ACG	220;220;218	A;C;G	186;185;186	penA.44.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2443	173.2	1	SNP	p	T502P	0	.	.	1504	1506	ACG	1860	1862	ACG	220;220;218	A;C;G	186;185;186	penA.44.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2443	173.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1983	1985	GGC	173;171;170	G;G;C	166;161;160	penA.44.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2443	173.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1992	1994	GGC	170;168;167	G;G;C,A	160;159;154,2	penA.44.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2443	173.2	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2010	2012	CTG	153;151;154	C,G;T;G	113,4;106;117	penA.44.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5822	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3299	176.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1772	1774	CCG	186;184;182	C;C;G	170;170;163	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2240	porA	1146	1146	99.65	porA.l15.c30.ctg.1	1930	115.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	600	600	C	145	C	134	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3036	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1602	188.7	0	.	p	.	0	T26A	NONSYN	76	78	ACC	490	492	GCC	254;253;255	G;C;C	238;238;235	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3036	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1602	188.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	526	528	GAA	240;240;238	G;A;A	227;228;225	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3036	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1602	188.7	0	.	p	.	0	N124S	NONSYN	370	372	AAT	784	786	AGT	254;252;251	A;G,A;T	231;225,1;227	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3036	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1602	188.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	814	816	GAT	250;245;240	G,A;A;T,C	229,1;225;224,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3036	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1602	188.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	937	939	TCA	252;248;247	T;C;A	232;227;228	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3036	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1602	188.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1066	1068	GTC	249;251;252	G;T;C,T	239;241;241,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3036	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1602	188.7	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1078	1080	TCT	250;248;254	T;C;T	240;239;246	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3036	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1602	188.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1396	1398	GCA	220;220;223	G;C;A	210;210;209	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3036	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1602	188.7	1	SNP	p	G120K	1	.	.	358	360	AAG	772	774	AAG	248;247;249	A;A;G	231;231;231	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3036	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1602	188.7	1	SNP	p	D121N	0	.	.	361	363	GAC	775	777	GAC	248;248;249	G;A,G;C	228;227,1;227	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3036	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1602	188.7	1	SNP	p	A121D	1	.	.	361	363	GAC	775	777	GAC	248;248;249	G;A,G;C	228;227,1;227	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11142	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4835	229.8	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2004	2006	CAT	247;246;248	C;A;T	233;230;232	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1160	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	848	134.7	1	SNP	p	V57M	1	.	.	169	171	ATG	425	427	ATG	243;242;243	A;T;G	224;225;225	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
